Safety of drug-eluting stents

Reviews in Cardiovascular Medicine

Volumn 11, Issue 4, 2010, Pages 187-199

  Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Drug eluting stents; Percutaneous revascularization; Stent thrombosis

Indexed keywords

ACETYLCHOLINE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EVEROLIMUS; GLYCOPROTEIN P; METHYLERGOMETRINE MALEATE; PACLITAXEL; POLYLACTIDE; POLYMER; PRASUGREL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; ZOTAROLIMUS; BIOMATERIAL;

ACUTE CORONARY SYNDROME; BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY ANEURYSM; CORONARY STENT; DRUG ABSORPTION; DRUG ELUTING STENT; DRUG RELEASE; GENETIC POLYMORPHISM; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT FRACTURE; STENT THROMBOSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; INSTRUMENTATION; PROSTHESIS; RISK ASSESSMENT; RISK FACTOR; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; BIOCOMPATIBLE MATERIALS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954428214     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0577     Document Type: Review

References (65)

1. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354:483-495.
2. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-3206.
3. Applegate RJ, Sacrinty MT, Kutcher MA, et al. "Off-label" stent therapy: 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51:607-614.
4. Douglas PS, Brennan JM, Anstrom KJ, et al. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology National Cardiovascular Data Registry. J Am Coll Cardiol. 2009;53:1629-1641.
5. Holmes DR Jr, Kerelakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56:1357-1365.
6. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344-2351. (Pubitemid 46685903)
7. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
8. Roukoz H, Bavry AA, Sarkees ML, et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009;122:581.e1-e10.
9. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routing clinical practice. 4-year results from a large 2-instirutional cohort study. J Am Coll Cardiol. 2008;52:1134-1140.
10. Kerelakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9-15. (Pubitemid 38344495)
11. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-1409.
12. Lasala JM, Cox DA, Dobies D, et al. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv. 2009;2:285-293.
13. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007,115:2435-2441. (Pubitemid 46717966)
14. Guagliumi G, Musumeci G, Sirbu V, et al; ODESSA Trial Investigators. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv. 2010;3:531-539.
15. Awata M, Kotani J, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910-916. (Pubitemid 47300915)
16. Hara M, Nishino M, Taniike M, et al. High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent. Am Heart J. 2010,159:905-910.
17. Takano M, Yamamoto M, Murakami D, et al. Lack of association between large angiographic late loss and low risk of In-stent thrombus: angioscopic comparison between paclitaxel- and sirolimus-eluting stents. Circ Cardiovasc Interv. 2008;1:20-27.
18. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130. (Pubitemid 40617065)
19. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168. (Pubitemid 46089732)
20. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813-818. (Pubitemid 46294748)
21. Airoldi F, Columbo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116: 745-754. (Pubitemid 47255992)
22. Serruys PW, Daemen J. Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation. 2007;115:1433-1439. (Pubitemid 46648379)
23. Tsai TT, Nallamothu BK, Bates ER. Letter by Tsai et al regarding article, "correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents". Circulation. 2006;114:e362. (Pubitemid 44268220)
24. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299: 532-539. (Pubitemid 351222546)
25. Sibbing D, Stegherr J, Braun S, et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of Clopidogrel treatment. J Am Coll Cardiol. 2010;55:558-565.
26. Bonello L, Tantry US, Marcucci R, et al; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet re-activity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
27. Tantry US, Kerelakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacologic interactions on clinical outcomes and mechanistic explanations. J Am Coll Cardiol Interv. 2011; in press.
28. Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation. 2010;122:1085-1090.
29. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
30. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008; 118:1138-1145.
31. Kukreja N, Onuma Y, Garcia-Garcia HM, et al; Interventional Cardiologists of the Thorax-center (2000 to 2005). The risk of stent thrombosis In patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv. 2009;2:534-541.
32. Chakravarty T, White AJ, Buch M, et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture. Am J Cardiol. 2010,106:1075-1080.
33. Nakazawa G, Finn AV, Vorpahl M, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery: a pathologic analysis. J Am Coll Cardiol. 2009;54:1924-1931.
34. Aoki J, Kirtane A, Leon MB, Dangas G. Coronary artery aneurysms after drug-eluting stent implantation. JACC Cardiovasc Interv. 2008,1:14-21. (Pubitemid 351445418)
35. Pendyala LK, Yin X, Li J, et al. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc Interv. 2009;2:1169-1177.
36. Kedhi E, Stone GW, Kereiakes DJ, et al. Stent thrombosis after everolimus-eluting versus paclitaxel-eluting coronary stents: insights from the SPIRIT H, SPIRIT III and SPIRIT IV and COMPARE pooled database. Circulation. 2010;122:A14593.
37. Kirtane A, Sood P, Applegate RJ, et al. Predictors of stent thrombosis after everolimus-eluting and paclitaxel-eluting stents: the pooled SPIRIT randomized trial experience at two years of follow-up. Circulation. 2010;122:A17174.
38. Stone G. SPIRIT IV: two-year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 23, 2010; Washington, DC.
39. Smits P. COMPARE: two-year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 23, 2010; Washington, DC.
40. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation. 2007; 116:2391-2398. (Pubitemid 350145074)
41. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56:S1-S42.
42. Hermlller J. Low stent thrombosis rates in 5,054 'real-world' patients from XIENCE V USA. Paper presented at: EuroPCR; May 25-28, 2010; Paris, France.
43. Eisenstein EL, Leon MB, Kandzari DE, et al; ENDEAVOR III Investigators. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009;2:1199-1207.
44. Rasmussen K, Maeng M, Kaltoft A, et al; SORT OUT III study group. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT-OUT III): a randomized controlled superiority trial. Lancet. 2010;375:1090-1099.
45. Leon MB, Nikolsky E, Cutlip DE, et al; ENDEAVOR IV Investigators. Improved late clinical safety and zotarolimus-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease) trial. JACC Cardiovasc Interv. 2010;3:1043-1050.
46. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363: 136-146.
47. Windecker S. Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for Coronary revascularization (LESSON 1). Paper presened at: 2010 European Society of Cardiology Congress; August 30, 2010; Stockholm, Sweden.
48. Jensen LO, Thayssen P, Hansen HS, et al. A prospective, randomized trial of everolimus-eluting and sirolimus-eluting stents in patients with coronary artery disease. Late Breaking Trial presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
49. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56:S42-S78.
50. Grube E. BIOFREEDOM. A prospective randomized trial of polymer-free biolimus A9-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
51. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006,113:273-279.
52. Moore P, Barlis P, Spiro J, et al. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. JACC Cardiovasc Interv. 2009;2:437-444.
53. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291-299.
54. Wilcox JN. Design specifications and preclinical results with a "drug-filled stent." Paper presented at: Transcatheter Cardiovascular Therapeutics; September 22, 2010; Washington, DC.
55. Takano M, Yamamoto M, Mizuno K. Two cases of coronary stent thrombosis very late after bare-metal stenting. JACC Cardiovasc Interv. 2009;2:1286-1287.
56. Hasegawa K, Ito M, Oda M, et al. Intravascular ultrasonic imaging of vulnerable plaque in a bare metal stent 10 years after implantation. Circulation. 2010;122:1341.
57. Takano M, Yamamoto M, Inami S, et al. Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents: extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol. 2009,55:26-32.
58. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910.
59. Onuma Y, Serruys PW, Ormiston J, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eurointervention. 2010;6:447-453.
60. Pollman MJ. Engineering a bioresorbable stent: REVA programme update. Eurointervention. 2009;5:F54-F57.
61. Waksman R. Current state of the absorbable metallic (magnesium) stent. Eurointervention. 2009;5:F94-F97.
62. Wykrzykowska J, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "Rosy" prophecy. Eurointervention. 2009;5: F7-F8.
63. Urban PM, Abizaid A, Banning A, et al. Stent thrombosis, bleeding, and antiplatelet therapy in the e-SELECT registry: one year follow-up of 15000 patients treated with the sirolimus-eluting CYPHER-SELECT stent plus. J Am Coll Cardiol. 2010;55: A125.E1166.
64. Lotan C, Meredith IT, Mauri L, et al; E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv. 2009; 2:1227-1235.
65. Ahmed WH, Zambahari R, Al-Rashdan I, et al. One-year outcomes with the Taxus Liberté stent In the real world: the Taxus Olympia registry (phase I). J Interv Cardiol. 2008;21:512-518.